Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Worapaka Manosroi has a total of 119 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prognostic factors and prognostic risk score of 30-day all-cause mortality in thyroid storm

    byĀ Pakpoom Chantrapitak, Worapaka Manosroi, Sittikul Thipbumrung, Pichitchai Atthakomol

    Thyroid storm is a life-threatening endocrine emergency with high mortality. Existing diagnostic score primarily focuses on diagnosis rather than predicting outcomes. This study aimed to identify prognostic factors and develop a practical clinical prognostic score for 30-day all-cause mortality in patients with thyroid storm. A retrospective cohort study was conducted at a tertiary care center in Thailand. Patients diagnosed with thyroid storm were included. To identify prognostic factors of 30-day all-cause mortality, clinical and biochemical variables were analyzed using multivariable logistic regression analysis presented with odds ratio (OR). A prognostic risk score was developed and internally validated using bootstrapping. Statistical significance p-value was set at < 0.05. A total of 115 patients were included, with a 30-day mortality rate of 13%. Significant prognostic factors of 30-day mortality included male sex (OR 4.34), hypertension (OR 2.54), SOFA score ≄ 2 (OR 9.93), and GCS ≤ 10 (OR 1.95). Based on these four variables, a weighted scoring system (total 8 points) was developed. The model demonstrated good discriminatory performance with an apparent AUC of 0.81, which remained robust at 0.79 (95% CI 0.69-0.91) after internal validation via bootstrapping. The prognostic factors and proposed clinical prognostic score, incorporating simple and readily available parameters, provides an effective tool for early risk stratification in thyroid storm. This score can facilitate prioritized intensive care admission. Further external validation is warranted to confirm its generalizability across diverse clinical settings. Not applicable.


  • Comparative Effects of Individual Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

    byĀ Nuttaya Wachiraphansakul, Thanawat Vongchaiudomchoke, Worapaka Manosroi, Chidchanok Ruengorn, Kajohnsak Noppakun, Tanun Ngamvichchukorn, Manish M. Sood, Kednapa Thavorn, Brian Hutton, Surapon Nochaiwong

    Aim: To compare the effects of individual glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on direct body composition among adults with overweight or obesity, with or without type 2 diabetes (T2D). Methods: We systematically searched six electronic databases and grey literature from inception to 3 November 2025, to identify all randomised controlled trials (RCTs) that investigated individual GLP‐1RAs on change in body composition from baseline among adults with overweight or obesity with or without T2D, without language restrictions. The main outcomes included total body fat (%), fat mass (kg), visceral adipose tissue (VAT) area (cm 2 ), subcutaneous adipose tissue (SAT) area (cm 2 ), liver fat content (%), total lean tissue (%) and lean mass (kg). A frequentist network meta‐analysis was employed using a random‐effects model and reported as standardised mean differences (SMDs). Certainty of evidence was appraised using the Confidence in Network Meta‐Analysis. Results: We identified 43 unique RCTs with 3379 participants that compared 17 different interventions or dosages with a control group. Regarding variations in treatment benefits on body composition, GLP‐1RAs subcutaneously were more efficacious than the control group in decreasing total body fat, fat mass, VAT, SAT and liver fat from baseline. No significant differences for change in total lean tissue were observed. However, subcutaneously, liraglutide 1.8 mg/day, semaglutide 1.0 mg—weekly and tirzepatide 15 mg—weekly (SMDs ranged from āˆ’1.09 to āˆ’0.50) significantly decreased lean mass from baseline. Conclusions: GLP‐1RAs substantially improve body composition‐related excess adiposity, but unfavourable effects on lean mass were observed, particularly at high doses.


  • Open Access

    Predictors of weight reduction effectiveness with liraglutide in diabetes mellitus type 2 patients: a retrospective cohort study

    byĀ Pitsinee Wangpattanamongkol, Worapaka Manosroi

    Background: GLP-1 receptor agonists (GLP-1RAs) are effective for treating type 2 diabetes mellitus (T2DM) and promoting weight loss, but not all patients respond similarly. This study aimed to identify predictors of significant weight reduction at 6 months in T2DM patients treated with liraglutide. Materials and methods: A retrospective analysis was conducted on 209 T2DM adults prescribed liraglutide at the Internal Medicine Department, Faculty of Medicine, Chiang Mai University between January 1, 2017, and December 31, 2022. Patients who could not tolerate or did not complete titration to 3.0 mg daily were excluded. Demographic, clinical, anthropometric, and biochemical data were obtained from electronic medical records. Logistic regression was used to identify clinical and biochemical factors associated with significant weight reduction (≄ 5% at 6 months), presented as odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was set at p < 0.05. Results: Of the 209 patients, 27.3% achieved significant weight reduction. Lower baseline body mass index (BMI) (OR 1.12, 95% CI 1.01–1.25, p = 0.036) and greater weight loss at 3 months (OR 2.22, 95% CI 1.67–3.03, p < 0.001) were significant predictors of weight reduction at 6 months, after adjusting for age, sex, baseline HbA1c, creatinine, systolic blood pressure, LDL cholesterol, and concomitant medications. Conclusion: Lower baseline BMI and early weight loss at 3 months predict significant weight reduction with liraglutide therapy. Identifying these simple, accessible predictors can improve patient selection and optimize weight control outcomes.


  • Open Access

    Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism

    byĀ Sittikul Thipbumrung, Worapaka Manosroi

    Current guidelines recommend discontinuing mineralocorticoid receptor antagonists (MRA) at least 4 weeks before adrenal venous sampling (AVS) in primary aldosteronism (PA) to avoid interference with the lateralization index (LI). However, discontinuing MRA can cause hypertension and hypokalemia. This study aimed to evaluate the impact of continuing MRA use prior to AVS. A 5-year retrospective cohort study of patients aged ≄ 18 with PA who underwent successful AVS was conducted. Patients were divided into two groups: those who continued MRA during AVS and those who discontinued it for at least 4 weeks prior. Outcomes included differences in LI, plasma renin activity (PRA) levels before AVS, and post-adrenalectomy outcomes. Linear regression analysis clustered by subtypes of PA was used to adjust for confounders. A total of 66 patients were included, with 30 (45.5%) in the continued MRA group and 36 (54.5%) in the discontinued MRA group. After adjustment for confounders, PRA levels before AVS showed no significant difference between the groups (β-coefficient 0.5, 95% CI -2.0 to 3.0; p = 0.239) and there was no significant difference in the LI between the continued and discontinued MRA groups (β-coefficient 7.9, 95% CI -27.8 to 43.7; p = 0.216). Clinical and biochemical success after unilateral adrenalectomy were similar between the two groups (p = 0.141 and p = 0.596, respectively). Continuing MRA prior to AVS did not appear to affect the interpretation of lateralization and may be a reasonable option for patients at high risk of complications from MRA withdrawal. Further prospective studies are needed to confirm these observations.


  • Open Access

    Factors predicting secondary hypertension in young adults with hypertension: a retrospective study

    byĀ Nicha Prasert, Worapaka Manosroi, Benya Hankamolsiri, Muslimah Wae-Uma, Papot Choonklai

    Hypertension in young adults is often due to secondary causes, and investigating these can be resource-intensive. This study aimed to identify clinical and biochemical markers that could suggest secondary hypertension in individuals under 40 years. A 6-year retrospective observational cohort study included 207 young adults with hypertension who were assessed for secondary causes such as hyperthyroidism, primary aldosteronism, Cushing’s syndrome, pheochromocytoma, and renovascular disease. Multivariable logistic regression was used to identify significant predictors, with a significance level set at p < 0.05. Secondary hypertension was diagnosed in 7 patients (3.4%). The most common diagnoses were primary aldosteronism and hyperthyroidism. Three significant clinical and biochemical predictors were identified: female (OR 4.56, p = 0.020), systolic blood pressure > 160 mmHg at the time of diagnosis (OR 1.44, p = 0.010), and serum potassium < 3.5 mEq/L (OR 3.69, p = 0.019). Several easy-to-obtain clinical and biochemical markers can help identify secondary hypertension in young adults. Individuals who do not have any of these predictors may have a lower likelihood of secondary hypertension; however, these markers should always be used in conjunction with a thorough clinical assessment and are not intended to serve as definitive criteria for diagnosis. Not applicable.


  • Open Access

    Predictors and Predictive Score of In-Hospital Mortality in Diabetic Ketoacidosis: A Retrospective Cohort Study

    byĀ Neera Munsakul, Worapaka Manosroi, Supawan Buranapin

    Background and Objectives: Diabetic ketoacidosis (DKA) is a critical complication of diabetes mellitus (DM). The primary objective of this study was to identify relevant clinical and biochemical predictors and create a predictive score for in-hospital DKA mortality. Materials and Methods: A 6-year retrospective cohort study of adult patients diagnosed with DKA and admitted to Chiang Mai University Hospital, a tertiary care center in Chiang Mai, Thailand, from 1 January 2015 to 31 December 2021, was conducted. Baseline clinical data and laboratory investigations were collected. The primary outcome was in-hospital mortality. Multivariable logistic regression analysis, clustered by type of diabetes, was performed to identify significant predictors. A predictive risk score was created using significant predictive factors identified by multivariable analysis. The results were presented as odds ratios (ORs) and 95% confidence intervals (CIs), with a significant p-value set at 55 years (OR 7.8, p = 0.007), female gender (OR 3.5, p < 0.001), anion gap > 30 mEq/L (OR 2.6, p = 0.003), hemoglobin levels < 10 g/dL (OR 16.9, p < 0.001), and the presence of cardiovascular disease (OR 1.3, p = 0.046). The predictive risk score ranged from 1 to 14 for low risk, and 14.5–23.5 for high risk of in-hospital mortality. The predictive performance of the scoring system was 0.82 based on the area under the curve, with a sensitivity of 73.8% and specificity of 96.4%. Conclusions: Multiple clinical and biochemical factors, along with a predictive risk score, could assist in predicting in-hospital mortality of DKA and serve as a guide for physicians to identify patients at high risk. Nevertheless, as the predictive score was internally validated with data from a single institution, external validation in diverse healthcare settings with larger datasets or prospective cohorts is crucial to confirm the model’s generalizability and predictive accuracy.


  • Open Access

    Effect of Vitamin D Supplementation on Muscle Function in Patients With I131-Induced Hypothyroidism: A Pilot Randomized Trial

    byĀ Sureephan Maneewan, Worapaka Manosroi, Panas Jesadaporn, Mattabhorn Phimphilai, Pratchaya Tipduangta

    Background There is a lack of data regarding the effect of vitamin D supplements in patients with I131-induced hypothyroidism. The primary aim of this study was to investigate the effect of vitamin D supplements on muscle function, and the secondary aim was to observe the effect on body composition, insulin resistance, and quality of life (QOL) in patients with I131-induced hypothyroidism. Methods In this pilot randomized placebo-controlled trial, patients with I131-induced hypothyroidism on a stable dose of levothyroxine were enrolled and allocated into 2 groups to receive oral vitamin D 20 000 IU weekly or placebo for 24 weeks. Baseline biochemical values, body composition, handgrip strength, the 5 times sit-to-stand test (5TSTS), homeostatic model assessment for insulin resistance (HOMA-IR), and QOL were measured before intervention and after 3 and 6 months in both groups. Mixed model regression analysis was used to compare the outcomes between the 2 groups. Significance was set at P value of < .05. Results There were 20 participants in each group. The time taken for 5TSTS in the vitamin D group was significantly lower than the placebo group at 3 (P = .032) and 6 months (P = .006). Other outcomes, including handgrip strength, body composition, HOMA-IR, and QOL, showed no significant difference between the 2 groups. Conclusion A supplement of vitamin D2 at 20 000 IU per week for 24 weeks could help improve performance in 5TSTS in patients with I131-induced hypothyroidism.

  • Metabolic Syndrome and Metabolic Dysfunction-Associated Steatotic Liver Disease in Premenopausal Women

    byĀ Pojsakorn Danpanichkul, Cheng Han Ng, Mark D. Muthiah, Kwanjit Duangsonk, Siwanart Kongarin, Karan Srisurapanont, Phakkamon Pingwang, Nonlawan Songmueang, Chalida Nonthasoot, Worapaka Manosroi, et al.


  • Open Access

    Plasma aldosterone response to ACTH stimulation test for diagnosis of primary aldosteronism: a cross-sectional study

    byĀ Worapaka Manosroi, Pichitchai Atthakomol, Piti Inthaphan, Supornthip Hintong

    The diagnosis of primary aldosteronism (PA) requires screening and confirmation testing. The present study examined whether the 1 µg ACTH stimulation test for plasma aldosterone concentration (PAC) can accurately diagnose PA by bypassing the regular confirmatory steps of PA diagnosis. A cross-sectional study with a total of 36 patients with an aldosterone-renin ratio (ARR) > 20 ng/dL per ng/m/hr were included. The confirmation test for PA was performed by saline infusion and the patients were categorized into PA and non-PA. PAC was collected at 20 and 40 min after 1 µg ACTH stimulation test. Multivariable logistic regression analysis was performed, and the associations are presented as odds ratios (OR) and 95% confidence intervals (CI). Diagnostic accuracy is presented as AuROC. Multivariable analysis found only PAC at 20 min after ACTH stimulation showed significant association with a diagnosis of PA (OR 1.18, 95%CI (0.99, 1.31), p = 0.040). AuROC for this value was 0.95 and the proposed cut-off was 52 ng/dL with a sensitivity of 71.4% and a specificity of 96.6%. Diagnosing PA may be aided by PAC at 20 min following 1 µg ACTH stimulation. This value may be used with patients for whom the confirmation test for PA cannot be conducted.


  • Open Access

    Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients

    byĀ Pojsakorn Danpanichkul, Worapaka Manosroi, Tharadon Nilsirisuk, Theetouch Tosukhowong

    Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a novel medication for treating type 2 diabetes (T2DM), which have the pleiotropic effect of weight reduction. This study aimed to evaluate clinical and biochemical predictors of effective weight reduction in T2DM patients who use various types of SGLT2i.Materials and methods: A retrospective study was conducted with 289 adults diagnosed with T2DM who were first prescribed SGLT2i either as monotherapy or add-on therapy. The primary outcome was the identification of clinical and biochemical factors that can potentially induce meaningful weight reduction (>3% in 1 year) in T2DM patients while using SGLT2 inhibitors. The relationship between predictors and significant weight loss was assessed using logistic regression analysis, including adjustment for confounding factors. Results are presented as odds ratios (ORs) with a 95% confidence interval (CI).Results: Among the 289 patients, 45.6% had significant weight loss following SGLT2i use. The significant clinical predictors were age >70 years old (OR 3.26, 95% CI 1.39-7.6, p=0.006), body mass index >25 kg/m2 (OR 1.02, 95% CI 1.01-1.05, p=0.049), and the use of sulfonylureas (OR 2.41, 95% CI 1.15-5.09, p=0.020). Additionally, the use of HCTZ showed significantly decreased odds of weight loss (OR 0.35, 95% CI 0.13-0.96, p=0.043).Conclusion: This research highlights multiple clinical factors that potentially can predict meaningful weight loss in patients with T2DM who are treated with SGLT2i. These findings could facilitate the identification of patients who might benefit from the weight loss effects of SGLT2i.